公开(公告)号：EP2239323A4

公开(公告)日：2012-05-23

申请号：EP09700866

申请日：2009-01-09

申请人： CHEMO SERO THERAPEUT RES INST ,  ASTELLAS PHARMA INC

发明人： UEHARA KENJI ,  HIGUCHI HIROFUMI ,  NAKASHIMA TOSHIHIRO ,  ISHIKAWA DAISUKE ,  YAMAMOTO NOBUCHIKA ,  FUJITA HIROTADA ,  SAKAI FUMIHIKO

IPC分类号： A61K39/395 ,  A61P29/00 ,  C07K16/28 ,  C07K16/46

CPC分类号： C07K16/2839 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

公开(公告)号：EP2348042A4

公开(公告)日：2012-03-28

申请号：EP09820642

申请日：2009-10-16

申请人： CHEMO SERO THERAPEUT RES INST

发明人： MATSUDA JUNICHI ,  KAMINAKA KAZUYOSHI ,  NOZAKI CHIKATERU

IPC分类号： C07K14/435 ,  A61K39/00 ,  A61K48/00 ,  A61P25/28 ,  C12N15/09

CPC分类号： C07K14/4711 ,  A61K39/0007 ,  A61K2039/53

公开(公告)号：EP2202306A4

公开(公告)日：2011-03-30

申请号：EP08837781

申请日：2008-10-08

申请人： CHEMO SERO THERAPEUT RES INST

发明人： SOEJIMA KENJI ,  IMAMURA TAKAYUKI ,  KAWAMURA RYOICHI ,  NAKATAKE HIROSHI ,  MAEYASHIKI ARISA ,  TOGO HITOMI

IPC分类号： C12N15/09 ,  A61K38/43 ,  A61P7/04 ,  C07K14/745 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02

CPC分类号： C12N9/6432 ,  A61K38/00 ,  C12Y304/21006

公开(公告)号：EP1860120A4

公开(公告)日：2009-07-01

申请号：EP06713179

申请日：2006-02-07

申请人： CHEMO SERO THERAPEUT RES INST

发明人： TORIKAI MASAHARU ,  NAKASHIMA TOSHIHIRO

IPC分类号： C07K16/46 ,  C07K16/00 ,  C12N15/09 ,  C12P21/08

CPC分类号： C07K16/00 ,  C07K16/1271 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/94

摘要： The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as "VL chain") of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.

公开(公告)号：EP1566181A4

公开(公告)日：2009-06-17

申请号：EP03812336

申请日：2003-11-28

申请人： CHEMO SERO THERAPEUT RES INST

发明人： KAWAMURA RYOICHI ,  NARUSE TAKESHI ,  HIRASHIMA MASAKI ,  KAMINAKA KAZUYOSHI ,  MATSUDA JUNICHI ,  MAEDA HIROAKI ,  NODA MAMI ,  WADA KEIJI

IPC分类号： A61K38/00 ,  A61K38/17 ,  A61P1/00 ,  A61P3/12 ,  A61P9/00 ,  A61P15/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/02 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/06 ,  A61P39/02 ,  A61P43/00 ,  C07K14/47

CPC分类号： A61K38/1709

摘要： It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

摘要翻译： 它旨在提供一种用于改善神经传递失败的新型药剂。 在优选的情况下，作为主要有效成分，含有以硒蛋白P为代表的含硒代半胱氨酸的蛋白质，该蛋白质的C末端肽或这些肽作为改善神经传递障碍的药剂。 该药物适用于改善由各种因素引起的神经传递衰竭疾病。

公开(公告)号：EP1741783A4

公开(公告)日：2009-05-27

申请号：EP05734670

申请日：2005-04-21

申请人： CHEMO SERO THERAPEUT RES INST

发明人： SUGIMURA KAZUHISA ,  NAKASHIMA TOSHIHIRO

IPC分类号： C12N15/13 ,  A61K31/7088 ,  A61K39/395 ,  A61K48/00 ,  A61P25/28 ,  C07K16/18 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/00 ,  C12P21/02 ,  G01N33/563 ,  G01N33/68

CPC分类号： G01N33/6896 ,  A61K31/7088 ,  A61K48/00 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/622 ,  G01N2333/4709 ,  G01N2800/2821

摘要： It is intended to provide a human amyloid beta peptide (hereinafter referred to as Abeta) antibody which binds to Abeta and inhibits the aggregation of Abeta molecules, and its antibody fragment. The above-described antibody or its antibody fragment has the variable region of human anti-Abeta antibody and strongly reacts with Abeta to thereby exert an effect of inhibiting the aggregation thereof. The above antibody and its antibody fragment are usable as Abeta detection reagents, preventives/remedies for Alzheimer's disease or diagnostics therefor.

公开(公告)号：EP1661989A4

公开(公告)日：2009-05-20

申请号：EP04770968

申请日：2004-07-28

申请人： CHEMO SERO THERAPEUT RES INST

发明人： MATSUYAMA REIKO ,  MAEDA HIROAKI

IPC分类号： C12N15/00 ,  C07K14/75 ,  C12N5/00

CPC分类号： C07K14/75

摘要： Recombinant cells having high fibrinogen production capability are prepared by, in the incorporation of genes coding for three types of proteins constituting fibrinogen, namely, alpha-chain (or variant of alpha-chain), beta-chain and gamma-chain (or variant of gamma-chain) in animal cells, causing the gene composition ratio to be such that the amount of gamma-chain (and/or variant of gamma-chain) gene is equal to or more but not exceeding 1000 times the amount of alpha-chain (and/or variant of alpha-chain) gene and beta-chain gene and further by employing baculovirus P35 gene.

公开(公告)号：EP1393746A4

公开(公告)日：2008-09-10

申请号：EP02717170

申请日：2002-04-16

申请人： CHEMO SERO THERAPEUT RES INST ,  KIRIN PHARMA KK

发明人： MAEDA HIROAKI ,  UMEHASHI MISAKO ,  NOZAKI CHIKATERU

IPC分类号： C12P21/08 ,  A61K39/085 ,  A61K39/09 ,  A61K39/104 ,  A61K39/108 ,  A61K39/20 ,  A61K39/245 ,  A61K39/395 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  C07K16/06 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12

CPC分类号： C07K16/1214 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/06 ,  C07K16/088 ,  C07K16/1081 ,  C07K16/1232 ,  C07K16/1271 ,  C07K16/1275

摘要： A human polyclonal antibody having an antibacterial and/or antiviral activity with a desired titer and a wide spectrum; and human polyclonal antibody composition for preventing and treating infections which contain this antibody. The human polyclonal antibody composition for preventing or treating infections contain the human polyclonal antibody which is obtained by administering as immunogen a bacterium and/or a virus or a component of the bacterium and/or the virus to a non-human animal having a human antibody gene locus and has an antibody titer against the bacterium and/or the virus exceeding that of human pool plasma.

公开(公告)号：EP1712918A4

公开(公告)日：2007-10-03

申请号：EP04807583

申请日：2004-12-22

申请人： MITSUBISHI KAGAKU IATRON INC ,  CHEMO SERO THERAPEUT RES INST

发明人： ONO TOMOKO ,  SOEJIMA KENJI ,  HIRASHIMA MASAKI ,  MORIKAWA WATARU ,  SAKATA YOICHI

IPC分类号： G01N33/573 ,  G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/95 ,  G01N2800/222 ,  G01N2800/226 ,  G01N2800/32 ,  Y10S436/811 ,  Y10T436/106664

摘要： A method of detecting the level of thrombus formation tendency or thrombosis through determining of the quantity of von Willebrand factor splitting enzyme. There is further disclosed a kit for detecting the level of thrombus formation tendency or thrombosis, which kit includes an antibody capable of specific binding to von Willebrand factor splitting enzyme, or a fragment of the antibody. The provided detection method and detection kit excel in convenience, speed and specificity.

公开(公告)号：EP1621615A4

公开(公告)日：2007-05-02

申请号：EP04727416

申请日：2004-04-14

申请人： CHEMO SERO THERAPEUT RES INST

发明人： KOYANAGI SATOSHI ,  KAWATSU KENJIRO ,  MURAKAMI TOSHIO ,  MIYATSU YOSHINOBU ,  MAEDA TOSHIHIRO ,  MIZOKAMI HIROSHI

IPC分类号： C12N15/09 ,  A61K35/64 ,  A61K38/17 ,  A61P37/08 ,  C07K14/435

CPC分类号： C07K14/43531 ,  A61K38/00 ,  A61K39/00

摘要： A method of purifying a modified acarian main allergen obtained by a technology of genetic manipulation; and a modified acarian main allergen having been purified by the purification method. In particular, a method of purifying a modified acarian main allergen obtained by a technology of genetic manipulation, which method is characterized by comprising the steps of (1) with the use of an MF membrane, washing and recovering an inclusion body containing a modified acarian main allergen obtained by a technology of genetic manipulation, (2) dissolving the inclusion body and performing refolding, (3) with the use of an ultrafiltration membrane, concentrating the resultant modified acarian main allergen containing solution and removing low-molecular components, (4) with the use of an anion exchanger, recovering the modified acarian main allergen as a non-adsorbed fraction, (5) with the use of hydrophobic gel, recovering the modified acarian main allergen as an adsorbed fraction and (6) with the use of an anion exchanger, recovering the modified acarian main allergen as an adsorbed fraction; and a modified acarian main allergen of high purity obtained by the purification method.